Drug to slow Alzheimer’s well tolerated outside of clinical trial setting
In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer’s disease who received lecanemab infusions at the Memory Diagnostic Center at WashU Medicine. Read the entire article on the Washington University Newsroom website by clicking here.